A Dutch study in the New England Journal of Medicine found bardoxolone methyl was not effective in reducing the odds of cardiovascular death or end-stage renal disease in type 2 diabetes patients with stage 4 chronic kidney disease. Examinations were conducted of 2,185 participants at a median follow-up of nine months, and more patients in the intervention arm were either hospitalized for heart failure or had died of the condition than in the placebo group. The study was ended early.
Bardoxolone methyl does not cut heart risk in diabetes patients with CKD
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||